

Special Issue

Defining the Nature of Neurological Complications after COVID-19 Vaccines

Message from the Guest Editor

COVID-19 pandemic has affected millions of people and imposed new scientific priorities. Several vaccines are approved for the use in multiple countries, showing to reduce COVID-19 infections and transmissions, number of hospitalizations and deaths in randomized controlled trials and effectiveness studies. The use of the vaccines shown rare adverse event including several potentially serious neurological complications, such as cortical sinus venous thrombosis, Bell's palsy, transverse myelitis and Guillain-Barré syndromes, leading to public concerns. Thus, the mass vaccination campaigns against COVID-19 infection sounds as an urgent call for researchers to independently assess the safety profile of vaccines in different populations and noncontrolled settings. Based on your extensive knowledge and clinical experience, we invite scholars to submit their work on the collected evidence (original report, original observation or review) to provide more clarity and knowledge regarding the occurrence and severity of the post-vaccination neurological implications.

Guest Editor

Dr. Maria Salsone

Institute of Molecular Bioimaging and Physiology, National Research Council, Milan, Italy

Deadline for manuscript submissions

closed (30 April 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/183729

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).